CN1961917A - Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof Download PDFInfo
- Publication number
- CN1961917A CN1961917A CN 200510115946 CN200510115946A CN1961917A CN 1961917 A CN1961917 A CN 1961917A CN 200510115946 CN200510115946 CN 200510115946 CN 200510115946 A CN200510115946 A CN 200510115946A CN 1961917 A CN1961917 A CN 1961917A
- Authority
- CN
- China
- Prior art keywords
- total
- herba erigerontis
- salviae miltiorrhizae
- extract
- radix ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, its preparing process and use thereof, wherein the composition mainly comprises one or two selected from ginseng saponins, total savianolic acid and Breviscapine, various injection preparations and pharmacologically allowable dose forms such as oral administration preparations can be produced through charging auxiliary materials. The preparation of the composition is mainly used for treating ischemic cerebral apoplexy, angina pectoris caused by coronary disease, cardiac functional insufficiency, apoplexy after-effect, hepatorenal syndrome, coronary heart disease, diabetes and complications. The preparation has the advantages of definite constituents, fine external appearance, controllable quality, and appreciable curative effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application, belong to technical field of medicaments.
Technical background
According to national health department's investigation statistics, 2004, ten thousand people died from cardiovascular and cerebrovascular disease surplus China had 260, and people's death was just arranged in average per 12 seconds, cardiovascular and cerebrovascular disease patient sum nearly 1.5 hundred million, and annual control expenditure surpasses 100,000,000,000.And the cardiovascular and cerebrovascular disease patient generally has hyperlipemia, hypertension, high blood viscosity, thrombosis, sclerosis of blood vessels, angiostenosis etc.If the Therapeutic Method of " medicine one is controlled, treated the head when the head aches, foot cure foot bitterly " according at present, so the patient must eat every day surplus " lipid lowerers, the depressor, fall the sticking medicine of blood, Pimobendane, thrombolytic medicine " etc. five, six kind even ten in the kind, Western medicine.Better prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and some outstanding treatment products also are provided; As: number of patent application is: 200410040029.9, name is called the patent application of " Chinese medicine preparation of chronic heart failure and preparation method thereof ", and the disease that it is used for the treatment for the treatment of cardiac and cerebral vascular diseases has definite curative effect; But in further investigation, find, adopt the effective site compatibility can not only reduce patient's dose, remove the strong composition of some toxic and side effects in the medicinal substances extract, the safety of preparation and the controllability of quality have been improved, greatly improve curative effect, and more help the molding of preparation, reduced some unnecessary technologies in the forming process.
Summary of the invention
The objective of the invention is to: a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease and its production and application is provided; The present invention is directed to prior art, according to cardiovascular and cerebrovascular disease such as coronary heart disease, cerebral thrombosis, alzheimer disease etc. all contract because of blood vessel is narrow, reason such as blood flow minimizing causes the diseases induced principle of blood supply insufficiency, on the basis of experiment screening, adopt one or both compatibilities of Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids and Herba Erigerontis total flavones to make preparation, optimize best prescription and technology; The product that obtains, particularly ejection preparation product can play activating blood circulation to dissipate blood stasis, TONGMAI SHULUO, improve blood circulation and metabolism.For example coronary heart disease is that coronary atherosclerosis causes myocardial ischemia, anoxia and the heart disease that causes, and the said medicine compatibility uses, and can play to improve the myocardial metabolism effect, increase coronary flow, and the blood that improves cardiac muscle is provided with the effect of allevating angina pectoris.The present invention has curative effect preferably for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, arrhythmia, cerebral thrombosis, alzheimer disease etc.But and the little patients life-time service of untoward reaction of the present invention.
The present invention constitutes like this: calculate according to percentage by weight, it is to be made one or both in X=Radix Salviae Miltiorrhizae total phenolic acids, the Herba Erigerontis total flavones by Radix Ginseng total saponins 1～99% and X99～1% and suitable adjuvant.Be preferably: calculate according to percentage by weight, it is to be made one or both in X=Radix Salviae Miltiorrhizae total phenolic acids, the Herba Erigerontis total flavones by Radix Ginseng total saponins 80～20% and X20～80% and suitable adjuvant.Say accurately: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 30～40%, Herba Erigerontis total flavones 30～40% and Radix Salviae Miltiorrhizae total phenolic acids 40～20% and suitable adjuvant.Radix Ginseng total saponins in the described prescription can be the highly finished product of panaxynol extract, Radix Ginseng water extract, Radix Ginseng water extract-alcohol precipitation extract, Radix Ginseng semi-bionic extraction thing, Radix Ginseng supercritical extract or above each extract; Herba Erigerontis total flavones can be the highly finished product of Herba Erigerontis alcohol extract, Herba Erigerontis water extract, Herba Erigerontis water extract-alcohol precipitation extract, Herba Erigerontis semi-bionic extraction thing, Herba Erigerontis supercritical extract or above each extract; Radix Salviae Miltiorrhizae total phenolic acids can be the highly finished product of tanshinol extract, Radix Salviae Miltiorrhizae water extract, Radix Salviae Miltiorrhizae water extract-alcohol precipitation extract, Radix Salviae Miltiorrhizae semi-bionic extraction thing, red sage root super critical extract or above each extract.Described composite preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.Described composite preparation can make on the basis that in Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids and the Herba Erigerontis total flavones one or both is prepared into liposome or pro-liposome.Contain saponin component, liposoluble ingredient and flavones ingredient in the preparation, calculate by weight percentage, saponin component content, liposoluble ingredient content and flavones ingredient content sum are not less than 50% of the total solid of deducting adjuvant amount and water quantities in the preparation in the preparation.Calculate according to percentage by weight, the content of total saponins is not less than 50% in the Radix Ginseng total saponins, and the content of total phenolic acid is not less than 50% in the Radix Salviae Miltiorrhizae total phenolic acids, and content of total flavone is not less than 50% in the Herba Erigerontis total flavones.
Effective site is preparation like this in the pharmaceutical composition of described treatment cardiovascular and cerebrovascular disease:
A, Herba Erigerontis total flavones effective site are preparations like this: get the Herba Erigerontis medical material, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Herba Erigerontis crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Herba Erigerontis total flavones effective site;
B, Radix Ginseng total saponins effective site are preparations like this: get the ginseng crude drug, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Ginseng crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Ginseng total saponins effective site;
C, Radix Salviae Miltiorrhizae total phenolic acids effective site are preparations like this: get red rooted salvia, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Salviae Miltiorrhizae crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Salviae Miltiorrhizae total phenolic acids effective site.
Injectable sterile block in the described preparation prepares like this: get Radix Ginseng total saponins and Herba Erigerontis total flavones, in the Radix Salviae Miltiorrhizae total phenolic acids one or both, press medicine and added mannitol than 1: 3 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 13 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 10～12 hours, kept more than 35 ℃ dry 2.5 hours, gland, promptly.
The pro-liposome of described compositions prepares like this: get one or both of Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir, supersound process, freezing, the dry powder that obtains sieves, promptly.
Described compositions is mainly used in diseases such as treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Compared with prior art, the applicant carried out lot of experiments, filtering out the prescription for the treatment of diseases such as angina pectoris is Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, and best compatibility scope is Radix Ginseng total saponins 40～30%, Herba Erigerontis total flavones 40～30% and Radix Salviae Miltiorrhizae total phenolic acids 20～40%.Adopt good, the steady quality of prepared product appearance of the present invention.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments.
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
We by antiplatelet aggregation test, suppress the mouse tail thrombotest, the prescription of different proportion has been carried out the screening test of system, wherein fill a prescription 1: model group gives normal saline; Prescription 2: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones=99/1; Prescription 3: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones=80/20; Prescription 4: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids/Herba Erigerontis total flavones=40/40/30; Prescription 5: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids/Herba Erigerontis total flavones=30/30/40; Prescription 6: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones=20/80; Prescription 7: Radix Ginseng total saponins/Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones=1/99; Prescription 8: positive controls, the result is as follows:
The prescription research conclusion
| Formula number | The screening and assessment index | |
| Platelet suppression ratio (%) | Thrombosis suppression ratio (%) | |
| 1 2 3 4 5 6 7 8 | 0.31％ 49.1％ 52.5％ 62.9％ 63.4％ 50.8％ 48.6％ 62.5％ | -0.33％ 21.1％ 34.5％ 41.9％ 42.3％ 33.2％ 25.4％ 41.5％ |
By experimental result as can be known, Radix Ginseng total saponins: Herba Erigerontis total flavones: the best compatibility scope of Radix Salviae Miltiorrhizae total phenolic acids is 40～30%: 40～30%: 20～40%.
Experimental example 2: injection Study on Forming
2.1 supplementary product kind and consumption are to the influence of powder pin
The applicant finds that in development suitable caffolding agent is powder injection formulation molding and stable key factor, and in order to improve the quality of this powder injection formulation, the applicant is under different support agent and the consumption thereof, and the quality of injectable powder is investigated.The result shows what mannitol was best suited for, and the amount ratio of itself and drug effective region is: 1: 3.
Various different amounts caffolding agents are to the influence of this injectable powder quality
| Medicine (mg/ml) | Gelatin hydrolysate (mg/ml) | Mannitol (mg/ml) | Glucose (mg/ml) | Color and luster | Dissolubility | Clarity | Mouldability |
| 10.00 10.00 10.00 10.00 10.00 10.00 10.00 | 0 30 40 0 0 0 0 | 0 0 0 30 40 0 0 | 0 0 0 0 0 30 40 | The pale yellow palm fibre of the pale yellow palm fibre of the pale yellow palm fibre of the pale yellow palm fibre of the pale yellow palm fibre of the pale yellow palm fibre of pale yellow palm fibre | Instant instant instant | Clear and bright difference difference good job is clear and bright | Not moulding moulded not moulding of or not of moulding |
By the result of last table as seen,, select an amount of gelatin hydrolysate for use through test of many times, good moldability, but clarity is poor; Glucose is insufficient formability then; And mannitol not only can hydrotropy, and mouldability etc. all tool is good, especially when itself and medicine than=1: in the time of 3, be 1: 3 so the present invention selects drug effective region consumption and mannitol amount ratio.
Experimental example 3: preparation pharmacodynamic experiment
Protective effect to Acute Myocardial Ischemia in Rats: get the SD rat; body constitution amount 230～250g; male and female half and half; be divided into model group (giving the equivalent normal saline every day), oral liquid group of the present invention (administration every day 60mg/kg), injection group of the present invention (administration every day 60mg/kg), liposome group of the present invention (administration every day 60mg/kg) and Radix Ginseng/Radix Salviae Miltiorrhizae/Herba Erigerontis 40/40/20 medical material proportioning injection group at random and (be called for short medical material compatibility group; administration every day 60mg/kg); every group 10; continuous 7 days, 1h ligation rat coronary artery left anterior descending branch after the last administration.Ventricle is got blood 3ml behind coronary ligation 3h, and centrifugal 5min prepares serum with the speed of 3000 * g, gets serum, measures corresponding index in the serum respectively with superoxide dismutase (SOD), malonaldehyde (MDA) test kit.Win rat heart and discharge hematocele in the chambers of the heart, inhale the branch that anhydrates, reject non-cardiac muscular tissues such as fatty blood vessel, wipe out atrium and right ventricle, stay left ventricle and weigh, calculate infarcted region (weight in wet base) and account for left ventricle (weight in wet base) percentage ratio with normal saline flushing and with filter paper.The results are shown in following table.
Influence to SOD, MDA in myocardial infarct size and the serum behind the rat coronary ligation
| Group | Heart infarction scope (%) | SOD(NU/ml) | MDA(nmol/ml) |
| Model group injection group of the present invention oral liquid group of the present invention liposome group of the present invention medical material compatibility group | 21.9±1.8 15.2±0.9 16.8±2.3 14.3±1.2 17.1±1.1 | 168.4±54.3 315.6±36.4 283.8±41.2 331.6±40.8 264.9±33.9 | 7.81±1.12 4.65±1.45 4.97±0.96 3.94±0.62 5.26±1.73 |
By experimental result as can be known, pharmaceutical preparation of the present invention can obviously improve SOD activity in the coronary ligation rat blood serum, has significantly suppressed the generation of MDA, and obviously reduces myocardial infarction district area, and the effect of lipidosome injection group is stronger.
Concrete embodiment
Embodiments of the invention 1: Radix Ginseng total saponins 40g Radix Salviae Miltiorrhizae total phenolic acids 20 Herba Erigerontis total flavones 40g
Get Radix Ginseng total saponins, Herba Erigerontis total flavones, Radix Salviae Miltiorrhizae total phenolic acids, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-15 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-40 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature, slowly heat up, 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 10～12 hours, kept more than 35 ℃ dry 2 hours, gland promptly gets the Injectable sterile block, one time 2,1 time on the one, with using behind the 250ml0.9% physiological saline solution.Calculate by weight percentage, in the injection saponin component content, liposoluble ingredient content and flavones ingredient content sum be deduction adjuvant amount and water quantities in the preparation total solid 85%.
Embodiments of the invention 2: Radix Ginseng total saponins 40g Radix Salviae Miltiorrhizae total phenolic acids 20g Herba Erigerontis total flavones 40g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 3: Radix Ginseng total saponins 30g Radix Salviae Miltiorrhizae total phenolic acids 40g Herba Erigerontis total flavones 30g
Get Radix Ginseng total saponins, Herba Erigerontis total flavones, Radix Salviae Miltiorrhizae total phenolic acids, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-15 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-40 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 10～12 hours, kept more than 35 ℃ dry 2 hours, gland promptly gets the Injectable sterile block.
Embodiments of the invention 4: Radix Ginseng total saponins 30g Radix Salviae Miltiorrhizae total phenolic acids 40g Herba Erigerontis total flavones 30g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 5: Radix Ginseng total saponins 35g Radix Salviae Miltiorrhizae total phenolic acids 30g Herba Erigerontis total flavones 35g
Get Radix Ginseng total saponins, Herba Erigerontis total flavones, Radix Salviae Miltiorrhizae total phenolic acids, press medicine and added mannitol than 1: 2 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5%, boiled 30 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 2 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-15 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-40 ℃, needs 2 hours approximately, keeps this temperature 2 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 12 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 10～12 hours, kept more than 35 ℃ dry 2 hours, gland promptly gets the Injectable sterile block.
Embodiments of the invention 6: Radix Ginseng total saponins 35g Radix Salviae Miltiorrhizae total phenolic acids 30g Herba Erigerontis total flavones 35g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate adds the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, boils, 4 ℃ of cold preservations are spent the night, coarse filtration, fine straining add the injection water, divide to install to ampoule bottle, seal sterilization, promptly get injection with small volume or concentrated solution for injection.
Embodiments of the invention 7: Radix Ginseng total saponins 90g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 10g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add an amount of water for injection dissolving, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, the saturated sodium hydroxide solution of reuse adjust pH to 6.5～8.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 8: Radix Ginseng total saponins 80g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 20g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, mixing adds an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 130 ℃ in inlet temperature, leaving air temp is 60 ℃, and air velocity is 20ms
-1Condition under spray drying get powder, packing promptly gets injectable sterile powder
Embodiments of the invention 9: Radix Ginseng total saponins 20g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 80g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, add 6% polyvinylpolypyrrolidone PVPP and 1.3% mannitol, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 10: Radix Ginseng total saponins 99g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 1g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, to be that 1.4: 1 polyethylene glycol 6000 is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously, be heated to 85-90 ℃, treat whole fusions after, 75-80 ℃ of insulation, mechanical high-speed stirs 15min to even, be transferred in the reservoir, the dropping liquid valve is regulated in 75～80 ℃ of insulations, splash in 30～35 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Embodiments of the invention 11: Radix Ginseng total saponins 1g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 99g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, in principal agent: the ratio of adjuvant=1.3: 1 adds calcium sulfate, by principal agent: the ratio adding microcrystalline Cellulose of adjuvant=1.1: 1, and press principal agent: the crospovidone of adjuvant=3: 1, evenly mixed, make soft material in right amount with 75% ethanol, cross 20 mesh sieve system granules, 55 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 12: Radix Ginseng total saponins 10g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 90g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, add 2 times of amount dextrin, 0.6% stevioside, 1.3% microcrystalline Cellulose, with the alcoholic solution system soft material of an amount of polyvinylpyrrolidone k30, granulate 70 ℃ of forced air dryings, granulate, granulate promptly gets granule.
Embodiments of the invention 13: Radix Ginseng total saponins 85g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 15g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, add the starch of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 14: Radix Ginseng total saponins 15g Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones 85g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Embodiments of the invention 15: Radix Ginseng total saponins 80g Radix Salviae Miltiorrhizae total phenolic acids, 20g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, add an amount of water for injection dissolving, add the glucose or the sodium chloride of ormal weight, by volume add 0.5% active carbon behind the mixed dissolution, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, the saturated sodium hydroxide solution of reuse adjust pH to 6.5～8.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining add the injection water, packing, sterilization promptly gets glucose or sodium chloride intravenous infusion.
Embodiments of the invention 16: Radix Ginseng total saponins 20g Radix Salviae Miltiorrhizae total phenolic acids 80g
Get Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, mixing adds an amount of water for injection dissolving, by volume add 0.5% active carbon, boil, keep little 30min that boils, cold slightly filtration, filtrate add the injection water to ormal weight, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, boil, 4 ℃ of cold preservations are spent the night, and coarse filtration, fine straining are 130 ℃ in inlet temperature, leaving air temp is 60 ℃, and air velocity is 20ms
-1Condition under spray drying get powder, packing promptly gets injectable sterile powder
Embodiments of the invention 17: Radix Ginseng total saponins 99g Radix Salviae Miltiorrhizae total phenolic acids 1g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids mix homogeneously, add 6% polyvinylpolypyrrolidone PVPP and 1.3% mannitol, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiments of the invention 18: Radix Ginseng total saponins 1g Radix Salviae Miltiorrhizae total phenolic acids 99g
With Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids mix homogeneously, will be that 1.4: 1 polyethylene glycol 6000 is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously is heated to 85-90 ℃, treat whole fusions after, 75-80 ℃ of insulation, mechanical high-speed are stirred 15min to evenly, are transferred in the reservoir, the dropping liquid valve is regulated in 75～80 ℃ of insulations, splashes in 30～35 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Embodiments of the invention 19: Radix Ginseng total saponins 80g Herba Erigerontis total flavones 20g
With Radix Ginseng total saponins and Herba Erigerontis total flavones mix homogeneously, in principal agent: the ratio of adjuvant=1.3: 1 adds calcium sulfate, by principal agent: the ratio adding microcrystalline Cellulose of adjuvant=1.1: 1, and press principal agent: the crospovidone of adjuvant=3: 1, evenly mixed, make soft material in right amount with 75% ethanol, cross 20 mesh sieve system granules, 55 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Embodiments of the invention 20: Radix Ginseng total saponins 20g Herba Erigerontis total flavones 80g
With Radix Ginseng total saponins and Herba Erigerontis total flavones mix homogeneously, add 2 times of amount dextrin, 0.6% stevioside, 1.3% microcrystalline Cellulose, with the alcoholic solution system soft material of an amount of polyvinylpyrrolidone k30, granulate 70 ℃ of forced air dryings, granulate, granulate promptly gets granule.
Embodiments of the invention 21: Radix Ginseng total saponins 1g Herba Erigerontis total flavones 99g
With Radix Ginseng total saponins and Herba Erigerontis total flavones mix homogeneously, add the starch of equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Embodiments of the invention 22: Radix Ginseng total saponins 99g Herba Erigerontis total flavones 1g
With Radix Ginseng total saponins and Herba Erigerontis total flavones mix homogeneously, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Embodiments of the invention 23: Radix Ginseng total saponins 40g Radix Salviae Miltiorrhizae total phenolic acids 40g Herba Erigerontis total flavones 20g
With Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, the phosphate buffer standardize solution, filtration sterilization, aseptic subpackaged, promptly get lipidosome injection.
Embodiments of the invention 24: Radix Ginseng total saponins 30g Radix Salviae Miltiorrhizae total phenolic acids 30g Herba Erigerontis total flavones 40g
With Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones mix homogeneously, be dissolved in the phosphate buffer (0.1M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 8min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Radix Ginseng total saponins among the above embodiment, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones can be with Radix Ginseng total saponins, Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones commercially available or that make by the inventive method, no matter be alcohol extract, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing or supercritical extract etc., but, wherein the total saponin content of Radix Ginseng total saponins is greater than 50%, total phenolic content of Radix Salviae Miltiorrhizae total phenolic acids is greater than 50%, the general flavone content of Herba Erigerontis total flavones can guarantee the therapeutic effect of product like this greater than 50%.
Claims (12)
1, a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: calculate according to percentage by weight, it is to be made one or both in X=Radix Salviae Miltiorrhizae total phenolic acids, the Herba Erigerontis total flavones by Radix Ginseng total saponins 1～99% and X 99～1% and suitable adjuvant.
2, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 1, it is characterized in that: calculate according to percentage by weight, it is to be made one or both in X=Radix Salviae Miltiorrhizae total phenolic acids, the Herba Erigerontis total flavones by Radix Ginseng total saponins 80～20% and X 20～80% and suitable adjuvant.
3, according to the pharmaceutical composition of claim 1 or 2 described treatment cardiovascular and cerebrovascular diseases, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Ginseng total saponins 30～40%, Herba Erigerontis total flavones 30～40% and Radix Salviae Miltiorrhizae total phenolic acids 40～20% and suitable adjuvant.
4, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～3, it is characterized in that: the Radix Ginseng total saponins in the described prescription can be the highly finished product of panaxynol extract, Radix Ginseng water extract, Radix Ginseng water extract-alcohol precipitation extract, Radix Ginseng semi-bionic extraction thing, Radix Ginseng supercritical extract or above each extract; Herba Erigerontis total flavones can be the highly finished product of Herba Erigerontis alcohol extract, Herba Erigerontis water extract, Herba Erigerontis water extract-alcohol precipitation extract, Herba Erigerontis semi-bionic extraction thing, Herba Erigerontis supercritical extract or above each extract, and Radix Salviae Miltiorrhizae total phenolic acids can be the highly finished product of tanshinol extract, Radix Salviae Miltiorrhizae water extract, Radix Salviae Miltiorrhizae water extract-alcohol precipitation extract, Radix Salviae Miltiorrhizae semi-bionic extraction thing, red sage root super critical extract or above each extract.
5, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease of claim 1～4, it is characterized in that: described composite preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and tablet, capsule, granule, drop pill, pellet, pill, soft capsule, oral liquid, oral cavity disintegration tablet or the dispersible tablet that makes with freeze-drying or spray drying method after the dilution.
6, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 5, it is characterized in that: described preparation can make on the basis that in Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids and the Herba Erigerontis total flavones one or both is prepared into liposome or pro-liposome.
7, according to the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: contain saponin component, liposoluble ingredient and flavones ingredient in the preparation, calculate by weight percentage, saponin component content, liposoluble ingredient content and flavones ingredient content sum are not less than 50% of the total solid of deducting adjuvant amount and water quantities in the preparation in the preparation.
8, according to the pharmaceutical composition of the described treatment cardiovascular and cerebrovascular disease of claim 4, it is characterized in that: calculate according to percentage by weight, the content of total saponins is not less than 50% in the Radix Ginseng total saponins, the content of total phenolic acid is not less than 50% in the Radix Salviae Miltiorrhizae total phenolic acids, and content of total flavone is not less than 50% in the Herba Erigerontis total flavones.
9,, it is characterized in that described drug effective region is preparation like this as the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6:
A, Herba Erigerontis total flavones effective site are preparations like this: get the Herba Erigerontis medical material, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Herba Erigerontis crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Herba Erigerontis total flavones effective site;
B, Radix Ginseng total saponins effective site are preparations like this: get the ginseng crude drug, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Ginseng crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Ginseng total saponins effective site;
C, Radix Salviae Miltiorrhizae total phenolic acids effective site are preparations like this: get red rooted salvia, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Salviae Miltiorrhizae crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Salviae Miltiorrhizae total phenolic acids effective site.
10, preparation of drug combination method according to any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: the Injectable sterile block of described compositions prepares like this: get Radix Ginseng total saponins and Herba Erigerontis total flavones, in the Radix Salviae Miltiorrhizae total phenolic acids one or both, press medicine and added mannitol than 1: 3 with supplementary product consumption, add 1800ml water for injection, stirring makes dissolving, with saturated sodium hydroxide solution adjust pH to 6.5～8.0, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.5% boiled coarse filtration 30 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 2.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-45 ℃, needs 2.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-45 ℃ of constant temperature slowly heats up 2～4 ℃/h, to the lowest total of the melting point temperature, the time is about 13 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 10～12 hours, kept more than 35 ℃ dry 2.5 hours, gland, promptly.
11, according to the preparation of drug combination method of the described treatment cardiovascular and cerebrovascular disease of claim 6, it is characterized in that: the pro-liposome of described compositions prepares like this: get one or both of Radix Ginseng total saponins and Radix Salviae Miltiorrhizae total phenolic acids, Herba Erigerontis total flavones, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
12, as the application of the pharmaceutical composition of any described treatment cardiovascular and cerebrovascular disease in the claim 1～6, it is characterized in that: described compositions is mainly used in the application in disease medicaments such as preparation treatment ischemia apoplexy, angina pectoris, cardiac insufficiency, apoplexy sequela, hepatorenal syndrome, heart and lung diseases, diabetes and complication thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115946 CN1961917A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115946 CN1961917A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1961917A true CN1961917A (en) | 2007-05-16 |
Family
ID=38081257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115946 Pending CN1961917A (en) | 2005-11-11 | 2005-11-11 | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1961917A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884666A (en) * | 2009-05-15 | 2010-11-17 | 黄小珊 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
-
2005
- 2005-11-11 CN CN 200510115946 patent/CN1961917A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884666A (en) * | 2009-05-15 | 2010-11-17 | 黄小珊 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1981800A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN1961917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961905A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961915A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961918A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961913A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961901A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961904A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961903A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961910A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1981801A (en) | Chinese-medicinal preparation for treating cardiovascular diseases, its production and use | |
| CN100998600A (en) | Traditional Chinese medicine preparation for treating cardiovascular or cerebrovascular diseases, preparing method and use thereof | |
| CN100998622A (en) | Traditional Chinese medicine preparations for treating cardiovascular and cerebrovascular diseases the preparation method and use thereof | |
| CN100998641A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN100998642A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, preparing method and use thereof | |
| CN100998643A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease, and preparing method and use thereof | |
| CN1961902A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1965919A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961919A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961914A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961922A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961899A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961921A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1961920A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |